View source for Glimepiride

{{MedTemplate
| generic           = Glimepiride
| brand             = Amaryl
| structure         =
| classes           = [[:Category:Sulfonylureas|Sulfonylurea (third-generation)]], [[:Category:Insulin_secretagogues|Insulin secretagogue]], [[:Category:Antihyperglycemic_agents|Antihyperglycemic agent]]
| uses              = <vote slug="type2-diabetes-use">Type 2 diabetes mellitus</vote>
| starting_dose     = 1-2 mg PO once daily with breakfast; titrate by glycemic response
| preparations      = 1 mg, 2 mg, 4 mg tablets
| fda_max           = 8 mg/d
| pill_id           =
| routes            = Oral
| onset             = 1-2 hours
| duration          = 24 hours
| halflife          = ~5-9 hours (parent and active metabolites combined)<ref name="amaryl-label">FDA Prescribing Information, Amaryl (glimepiride), Sanofi-Aventis, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020496s029lbl.pdf</ref>
| bioavailability   = ~100% (oral; not significantly affected by food)<ref name="amaryl-label" />
| pregnancy         = Avoid; switch to insulin. Neonatal hypoglycemia reported.{{citation needed}}
| legal             = [[USLegal:Prescription only|Rx-only]] in US
| mechanism         = <vote slug="glimepiride-mech-claim">Glimepiride closes pancreatic β-cell ATP-sensitive potassium channels at a distinct binding site on SUR1, producing membrane depolarization, calcium entry, and glucose-independent insulin release.</vote> Compared with glyburide, glimepiride has a more pancreas-specific binding profile with less impact on cardiac KATP channels (relevant in the ischemic preconditioning debate) and a lower hypoglycemia rate at equieffective doses. CYP2C9 substrate; PGx genotype affects clearance.
}}

== References ==
<references />